Medicine and Dentistry
Adaptive Radiation
15%
Adaptive Radiotherapy
11%
Adjuvant Chemotherapy
9%
Adverse Event
9%
Brain Metastasis
19%
Breathing
12%
Cancer
8%
Chemoradiotherapy
15%
Chest
7%
Clinical Stage
13%
Clinical Trial
14%
Comorbidity
7%
Computer Assisted Tomography
12%
Diseases
17%
Esophageal Cancer
11%
Esophagectomy
7%
Glioblastoma
6%
Hazard Ratio
12%
Image-Guided Radiation Therapy
6%
Immunotherapy
10%
In Silico
6%
Intensity Modulated Radiation Therapy
11%
Lung
20%
Lung Cancer
39%
Magnetic Resonance Imaging
16%
Malignant Neoplasm
20%
Meningioma
11%
Metastatic Carcinoma
10%
Neoplasm
42%
Non Small Cell Lung Cancer
86%
Non-Small Cell Lung Cancer
14%
Odds Ratio
8%
Oncology
20%
Overall Survival
50%
Phase I Trials
9%
Polyethylene Terephthalate
8%
Progression Free Survival
14%
Proportional Hazards Model
7%
Proton Therapy
7%
Radiation Oncologist
7%
Radiation Oncology
11%
Radiation Therapy
100%
Recurrent Disease
11%
Stereotactic Body Radiation Therapy
86%
Stereotactic Radiosurgery
22%
Surgery
34%
Temozolomide
8%
Thoracic Wall
6%
Treatment Planning
10%
Ventricular Tachycardia
15%
Keyphrases
Adaptation Planning
9%
Adaptive Radiation Therapy
9%
Adaptive Radiotherapy
18%
Adjuvant Chemotherapy
10%
At-risk
13%
Brain Metastases
20%
Cardiac Ablation
11%
Chemoradiation
12%
Chemotherapy
11%
Clinical Experience
8%
Concurrent Chemotherapy
9%
Confidence Interval
23%
Dose Escalation
13%
Dosimetric
8%
Dosimetric Predictors
8%
Early-stage Lung Cancer
12%
Esophageal Cancer
10%
Hazard Ratio
15%
Intensity-modulated Radiation Therapy
8%
Internal Target Volume
12%
Local Control
21%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
21%
Lung Cancer
20%
Lung Cancer Brain Metastases
7%
Magnetic Resonance Imaging
12%
Maximum Intensity Projection
7%
National Cancer Database
15%
Non-small Cell Lung Cancer (NSCLC)
66%
NRG Oncology
25%
Odds Ratio
8%
Organs at Risk
11%
Overall Survival
47%
Phase I Trial
11%
Phase II Trial
9%
Planning Target Volume
10%
Progression-free Survival
15%
Radiation Oncology
11%
Radiation Therapy
59%
Radiation Therapy Oncology Group
9%
Radiotherapy
19%
Stage I Lung Cancer
15%
Stage III Non-small Cell Lung Cancer
9%
Stereotactic Body Radiation Therapy
62%
Stereotactic Body Radiotherapy
20%
Stereotactic Radiosurgery
22%
Surgical Resection
11%
Temozolomide
10%
Thorax
9%
Tumor
17%
Ventricular Tachycardia
15%